Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation

J Thorac Oncol. 2021 Sep;16(9):e72-e76. doi: 10.1016/j.jtho.2021.07.013.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Epidermal Growth Factor
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation

Substances

  • Epidermal Growth Factor
  • EGFR protein, human
  • ErbB Receptors